Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride
- PMID: 20029833
- PMCID: PMC2840194
- DOI: 10.1002/syn.20734
Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride
Abstract
The amphetamine challenge, in which positron emission tomography (PET) or single photon emission computed tomography radioligand binding following administration of amphetamine is compared to baseline values, has been successfully used in a number of brain imaging studies as an indicator of dopaminergic function, particularly in the striatum. [(18)F] fallypride is the first PET radioligand that allows measurement of the effects of amphetamine on D2/D3 ligand binding in striatum and extra-striatal brain regions in a single scanning session following amphetamine. We scanned 15 healthy volunteer subjects with [(18)F] fallypride at baseline and following amphetamine (0.3 mg/kg) using arterial plasma input-based modeling as well as reference region methods. We found that amphetamine effect was robustly detected in ventral striatum, globus pallidus, and posterior putamen, and with slightly higher variability in other striatal subregions. However, the observed effect sizes in striatum were less than those observed in previous studies in our laboratory using [(11)C] raclopride. Robust effect was also detected in limbic extra-striatal regions (hippocampus, amygdala) and substantia nigra, but the signal-to-noise ratio was too low to allow accurate measurement in cortical regions. We conclude that [(18)F] fallypride is a suitable ligand for measuring amphetamine effect in striatum and limbic regions, but it is not suitable for measuring the effect in cortical regions and may not provide the most powerful way to measure the effect in striatum.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2840194/bin/nihms164321f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2840194/bin/nihms164321f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2840194/bin/nihms164321f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2840194/bin/nihms164321f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2840194/bin/nihms164321f5.gif)
Similar articles
-
Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET.Brain Res. 2005 Jan 25;1032(1-2):77-84. doi: 10.1016/j.brainres.2004.11.005. Brain Res. 2005. PMID: 15680944
-
Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans.Neuropsychopharmacology. 2006 May;31(5):1016-26. doi: 10.1038/sj.npp.1300916. Neuropsychopharmacology. 2006. PMID: 16237395
-
Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans.Synapse. 2008 Jun;62(6):399-408. doi: 10.1002/syn.20506. Synapse. 2008. PMID: 18361438 Clinical Trial.
-
Toward whole-brain dopamine movies: a critical review of PET imaging of dopamine transmission in the striatum and cortex.Brain Imaging Behav. 2019 Apr;13(2):314-322. doi: 10.1007/s11682-017-9779-7. Brain Imaging Behav. 2019. PMID: 29071465 Free PMC article. Review.
-
The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain.Curr Pharm Des. 2003;9(8):673-96. doi: 10.2174/1381612033391135. Curr Pharm Des. 2003. PMID: 12570798 Review.
Cited by
-
Deficit of satellite oligodendrocytes of neurons in the rostral part of the head of the caudate nucleus in schizophrenia.Eur Arch Psychiatry Clin Neurosci. 2024 Jul 29. doi: 10.1007/s00406-024-01869-x. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 39073446
-
Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment.Mol Psychiatry. 2023 Jul;28(7):2811-2825. doi: 10.1038/s41380-023-02065-4. Epub 2023 Apr 21. Mol Psychiatry. 2023. PMID: 37085712 Free PMC article.
-
Antipsychotics-Induced Changes in Synaptic Architecture and Functional Connectivity: Translational Implications for Treatment Response and Resistance.Biomedicines. 2022 Dec 8;10(12):3183. doi: 10.3390/biomedicines10123183. Biomedicines. 2022. PMID: 36551939 Free PMC article. Review.
-
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics.Biomolecules. 2022 Jun 29;12(7):909. doi: 10.3390/biom12070909. Biomolecules. 2022. PMID: 35883465 Free PMC article. Review.
-
Amphetamine-induced dopamine release and impulsivity in Parkinson's disease.Brain. 2022 Oct 21;145(10):3488-3499. doi: 10.1093/brain/awab487. Brain. 2022. PMID: 34951464 Free PMC article. Clinical Trial.
References
-
- Aalto S, Bruck A, Laine M, Nagren K, Rinne JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D-2 receptor ligand [C-11]FLB 457. Journal of Neuroscience. 2005;25(10):2471–2477. - PMC - PubMed
-
- Aalto S, Hirvonen J, Kaasinen V, Hagelberg N, Kajander J, Nagren K, Seppala T, Rinne JO, Scheinin H, Hietala J. The effects of d-amphetamine on extrastriatal dopamine D-2/D-3 receptors: a randomized, double-blind, placebo-controlled PET study with [C-11]FLB 457 in healthy subjects. European Journal of Nuclear Medicine and Molecular Imaging. 2009;36(3):475–483. - PubMed
-
- Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O'Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biological Psychiatry. 2004;55(10):1001–1006. - PubMed
-
- Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Anjilvel S, Pidcock J, Guo NN, Lombardo I, Mann JJ, Van Heertum R, Foged C, Halldin C, Laruelle M. Measurement of striatal and extrastriatal dopamine D-1 receptor binding potential with [C-11]NNC 112 in humans: Validation and reproducibility. J Cerebr Blood F Met. 2000;20(2):225–243. - PubMed
-
- Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999;32(2):93–109. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources